Showing results (171-180 of 344) with videos related to
Sort By:
Pageof 35
International Journal of Hematology|May 26, 2005
Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study GroupChihiro Shimazaki, Hiroshi Fujii, Takashi Yoshida, et al.Cancer Science|November 5, 2021
Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphomaYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.Blood Advances|May 21, 2020
Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphomaMasato Saito, Toshihiko Ishii, Itaru Urakawa, et al.Journal of Vascular and Interventional Radiology : JVIR|January 25, 2025
Ethiodized Oil Emulsion for Sustained Release of Anti-PD-L1 AntibodiesHiroki Satomura, Yasushi Kimura, Norifumi Kennoki, et al.The Journal of Craniofacial Surgery|November 5, 2021
Scarring Caused by the Percutaneous Approach to Fractures of the Orbit and Orbital RimKazuya Kashiyama, Hiroki Yano, Yoshinobu Imamura, et al.Japanese Journal of Radiology|May 6, 2026
Efficacy and safety of conventional transarterial chemoembolization for hepatocellular carcinoma using a glass membrane emulsification device: comparison with a three-way stopcockYusuke Ono, Yasushi Kimura, Yu Masuda, et al.Blood Cancer Journal|May 2, 2018
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX studyKenshi Suzuki, Meletios A Dimopoulos, Naoki Takezako, et al.Oncogene|July 27, 2005
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myelomaAtsushi Suzuki, Shinsuke Iida, Miyuki Kato-Uranishi, et al.Frontiers in Oncology|March 27, 2025
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature reviewFrancesca Gay, Elena Zamagni, Craig Emmitt Cole, et al.International Journal of Hematology|August 19, 2021
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trialKenshi Suzuki, Chang-Ki Min, Kihyun Kim, et al.Pageof 35